The proangiogenic phenotype of tumor-derived endothelial cells is reverted by the overexpression of platelet-activating factor acetylhydrolase

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5710-5718

  Doublier, Sophie ^a   Ceretto, Monica ^a   Lupia, Enrico ^b   Bravo, Stefania ^a   Bussolati, Benedetta ^a   Camussi, Giovanni ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Dipartimento di Medicina Interna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL HYDROLASE; HYDROLASE; MATRIGEL; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; CD40 LIGAND; CELL LINE, TUMOR; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICE; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET ACTIVATING FACTOR; THROMBIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35348905586     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0412     Document Type: Article

References (49)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
3. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. Arterioscler Thromb Vasc Biol 1997;17:1193-202.
4. Ruoslahti E, Rajotte D. An address system in the vasculature of normal tissue and tumors. Annu Rev Immunol 2000;18:813-27.
5. Miebach S, Grau S, Hummel V, Rieckmann P, Tonn JC, Goldbrunner RH. Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. J Neurooncol 2006;76:39-48.
6. Hida K, Hida Y, Amin DN, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004;64:8249-55.
7. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003;17:1159-61.
8. Grange C, Bussolati B, Bruno S, Fonsato V, Sapino A, Camussi G. Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep 2006;15:381-6.
9. Fonsato V, Buttiglieri S, Deregibus M C, et al. Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis. Am J Pathol 2006;168:706-13.
10. Bussolati B, Grange C, Bruno S, et al. Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp Cell Res 2006;312:913-24.
11. Prescott SM, Zimmerman GA, McIntyre TM. Platelet-activating factor. J Biol Chem 1990;265:17381-4.
12. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000;80:1669-99.
13. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003;40:643-72.
14. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem 1997;272:17895-8.
15. Tjoelker L W, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549-53.
16. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003;42:93-114.
17. Montrucchio G, Lupia E, Battaglia E, Bussolino F, Emanuelli G, Camussi G. Tumor-necrosis factor α-induced angiogenesis depends on "in situ" platelet-activating factor biosynthesis. J Exp Med 1994;180:377-82.
18. Brizzi MF, Battaglia E, Montrucchio G, et al. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res 1999;84:785-96.
19. Montrucchio G, Lupia E, Battaglia E, et al. Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine Matrigel model. Arterioscler Thromb Vasc Biol 2000;20:80-8.
20. Del Sorbo L, Arese M, Giraudo E, et al. Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat. Eur J Immunol 2001;31:376-83.
21. Russo S, Bussolati B, Deambrosis I, Mariano F, Camussi G. Platelet-activating factor mediates CD40-dependent angiogenesis and endothelial-smooth muscle cell interaction. J Immunol 2003;171:5489-97.
22. Seo KH, Lee HS, Jung B, et al. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-κB. Cancer Res 2004;64:6482-8.
23. Maliba R, Lapointe S, Neagoe PE, Brkovic A, Sirois MG. Angiopoietins-1 and -2 are both capable of mediating endothelial PAF synthesis: intracellular signalling pathways. Cell Signal 2006;18:1947-57.
24. Bussolino F, Arese M, Montrucchio G, et al. Platelet-activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest 1995;96:940-52.
25. Montrucchio G, Sapino A, Bussolati B, e al. Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol 1998;153:1589-96.
26. Maggi M, Bonaccorsi L, Finetti G, et al. Platelet-activating factor mediates an autocrine proliferative loop in the endometrial adenocarcinoma cell line HEC-1A. Cancer Res 1994;54:4777-84.
27. Biancone L, Cantaluppi V, Boccellino M, et al. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. Am J Pathol 1999;155:1731-9.
28. Bussolati B, Biancone L, Cassoni P, et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 2000;157:1713-25.
29. Ishii S, Nagase T, Tashiro F, et al. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis intransgenic mice overexpressing platelet-activating factor receptor. EMBO J 1997;16:133-42.
30. Biancone L, Cantaluppi V, Del Sorbo L, Russo S, Tjoelker LW, Camussi G. Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth. Clin Cancer Res 2003;9:4214-20.
31. Bussolati B, Assenzio B, Deregibus MC, Camussi G. The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med 2006;84:852-63.
32. Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, Ferrando U, Camussi G. CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006;169:2223-35.
33. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549-53.
34. Blank ML, Hall MN, Cress EA, Snyder F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasmaacetylhydrolase: higher activities in hypertensive rats. Biochem Biophys Res Commun 1983;113:666-71.
35. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-7.
36. Camussi G, Montrucchio G, Lupia E, et al. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol 1995;154:6462-501.
37. McManus LM, Woodard DS, Deavers SI, Pinckard SI. PAF molecular heterogeneity: pathobiological implications. Lab Invest 1993;69:639-48.
38. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-28.
39. O'Flaherty JT, Redman JF, Schmitt JD, et al. 1-O-Alkyl-2- N-methylcarbamyl-glycerophosphocholine: a biologically potent, non-metabolizable analog of platelet-activating factor. Biochem Biophys Res Commun 1987;147:18-24.
40. Bernatchez PN, Tremblay F, Rollin S, Neagoe PE, Sirois MG. Sphingosine 1-phosphate effect on endothelial cell PAF synthesis: role in cellular migration. J Cell Biochem 2003;90:719-31.
41. Ko HM, Kang JH, Choi JH, Park SJ, Bai S, Im SY. Platelet-activating factor induces matrix metalloproteinase-9 expression through Ca(2+)-or PI3K-dependent signaling pathway in a human vascular endothelial cell line. FEBS Lett 2005;579:6451-8.
42. Seo KH, Ko HM, Choi JH, et al. Essential role for platelet-activating factor-induced NF-κB activation in macrophage-derived angiogenesis. Eur J Immunol 2004;34:2129-37.
43. SY Im, Ko HM, Kim JW, et al. Augmentation of tumor metastasis by platelet-activating factor. Cancer Res 1996;56:2662-5.
44. Melnikova VO, Mourad-Zeian AA, Lev DC, Bar-Eli M. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem 2006;281:2911-22.
45. Bazan NG. The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling. Cell Mol Neurobiol 2006;26:899-911.
46. Heon Seo K, Ko HM, Kim HA, et al. Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-κB activation. Cancer Res 2006;66:4681-6.
47. Matsuzawa A, Hattori K, Aoki J, Arai H, Inoue K. Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II. J Biol Chem 1997;272:32315-20.
48. Camussi G, Montrucchio G, Lupia E, Soldi R, Comoglio PM, Bussolino F. Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. J Immunol 1997;158:1302-9.
49. Negro Alvarez JM, Miralles Lopez JC, Ortiz Martinez JL, Abellan Alemmam A, Rubio del Barrio R. Platelet-activating factor antagonists. Allergol Immunopathol 1997;25:249-58.